We recently published our article Top 5 AI-Powered Healthcare Stocks That Can Make You Rich. To read the full article, head on to Top 10 AI-Powered Healthcare Stocks That Can Make You Rich. In this piece, we take a closer look at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer sitting quietly in the corner of the healthcare industry as a futuristic idea that hospitals, doctors, insurers, and investors can afford to ignore. It is now moving directly into clinics, back offices, diagnostic workflows, patient scheduling systems, hospital budgets, and even the way medical professionals manage their limited time. That is why the rise of AI-powered healthcare stocks, healthcare AI companies, medical technology stocks, digital health stocks, healthcare automation stocks, and artificial intelligence stocks in healthcare has become one of the more closely watched investment themes on Wall Street. For investors looking for the best AI healthcare stocks to buy, the story is no longer just about science fiction, robots in hospitals, or fancy algorithms reading scans. It is increasingly about productivity, cost savings, clinical accuracy, patient capacity, and the possibility that artificial intelligence could help solve some of the healthcare system’s most stubborn problems.
On June 9, Reuters reported that Philips’ Future Health Index survey found that artificial intelligence improved clinical accuracy, increased patient capacity, and helped healthcare providers save money. That matters because healthcare is one of the few industries where speed, accuracy, and cost control are not just business concerns; they can directly affect patient outcomes. The survey was conducted by research consultancy Vitreous World across 10 countries between February and April, covering 2,011 healthcare professionals and 20,085 patients. That is a large enough sample to give investors a useful look at how artificial intelligence is being received not only by clinicians but also by the patients who are increasingly exposed to AI-driven health tools, digital health platforms, and medical technology systems.
Philips North America CEO Jeff DiLullo told Reuters that clinicians using artificial intelligence could see an additional five patients per week on average. At first glance, five extra patients may not sound dramatic, but across a hospital network, regional clinic group, or national healthcare system, that number can become a major productivity story. Healthcare investors know that capacity is one of the most important issues in the industry. Many hospitals are dealing with staffing pressure, rising costs, physician burnout, longer patient wait times, and growing demand from aging populations. If AI tools can help clinicians see more patients without reducing quality, then the technology becomes more than a nice-to-have upgrade. It becomes a business and operational tool with real economic value.
The Trivia Behind AI in Healthcare: It Started Small, But the Stakes Are Now Huge
The interesting trivia behind artificial intelligence in healthcare is that many of its earliest practical uses were not glamorous at all. While investors often imagine AI immediately diagnosing cancer, discovering breakthrough drugs, or replacing human decision-making, the more common use cases have been far more basic and practical. Reuters noted that clinicians generally use artificial intelligence for administrative work, including data collection and scheduling. That sounds ordinary, but in healthcare, ordinary work consumes a massive amount of time. Doctors, nurses, and clinical teams spend hours dealing with paperwork, documentation, patient records, billing coordination, scheduling, and repetitive data tasks. If artificial intelligence can reduce that burden, it can free up healthcare professionals to focus more on patient care.
That is one reason the AI in healthcare market has become such an important theme for investors. The opportunity is not limited to one type of company. It touches health insurers, hospital technology providers, medical device companies, diagnostics firms, drug discovery platforms, cloud computing companies, software vendors, robotic surgery companies, and data analytics providers. In simple terms, artificial intelligence is trying to make healthcare smarter from multiple angles. It can support physicians in diagnosis, help radiologists analyze images, assist pharmaceutical companies in drug discovery, improve hospital workflow, automate insurance claims, detect fraud, personalize treatment, manage patient records, and forecast health risks before they become more expensive problems.
That broad opportunity is why hedge funds, analysts, and long-term investors continue to pay close attention to AI-powered healthcare stocks. Unlike some speculative technology themes, healthcare AI has a direct connection to real-world problems. Hospitals need to do more with less. Insurers need better data. Doctors need better workflow support. Patients want faster answers. Governments want healthcare systems to become more efficient. Pharmaceutical companies want to reduce the time and cost of drug development. That combination gives artificial intelligence a potentially massive role in the next stage of healthcare innovation.
AI Is Helping Doctors, But the Industry Still Has Trust Issues
The Philips Future Health Index survey also showed that around 30% of surveyed doctors said artificial intelligence has resulted in significant budget savings, while 36% said AI boosted the number of patients they treated weekly. Those figures are important because they suggest that artificial intelligence is already delivering measurable value for some healthcare professionals. From an investment standpoint, this is exactly the kind of evidence that can support the bull case for healthcare AI stocks, medical AI stocks, digital health companies, and AI-driven healthcare platforms. Investors do not only want exciting technology. They want adoption, measurable results, and a clear path to revenue growth.
Still, the AI healthcare story is not all smooth sailing. The same survey revealed that 77% of clinicians believed AI training was still unavailable, inadequate, or inconsistent. That is a serious issue. Healthcare is not like casual consumer technology, where users can experiment freely and fix mistakes later. In medicine, the consequences of bad decisions can be severe. If doctors and clinicians are expected to use AI tools, they need training, proper oversight, clear standards, reliable systems, and confidence that the technology supports rather than complicates their work. Without that, even the most advanced artificial intelligence platform can face slow adoption.
This is where the market needs to be careful. The rise of AI-powered healthcare stocks may create exciting opportunities, but investors should not assume every company with an AI label will become a winner. Healthcare is highly regulated, clinically sensitive, and deeply complex. Artificial intelligence systems must be accurate, explainable, secure, and properly integrated into existing workflows. A tool that looks impressive in a demo may struggle inside a hospital system that uses older software, limited staffing, strict compliance rules, and complicated reimbursement models. That is why the best AI healthcare stocks to buy are often companies that combine innovation with credibility, scale, data access, regulatory awareness, and practical use cases.
Insurers Are Watching Closely, and Not Always Happily
Another important part of the AI healthcare story is the tension between health systems and insurers. Health insurers, including Centene, have criticized the use of artificial intelligence by health systems, claiming that it has aggressively or inappropriately triggered increased reimbursement payments. That detail is important because healthcare is not only about doctors and patients. It is also about payments, coding, claims, billing, reimbursement, and insurance rules. If artificial intelligence helps hospitals identify more billable services or improves coding accuracy, health systems may see higher revenue. But insurers may argue that some AI-driven billing practices increase costs unfairly or too aggressively.
For investors, this creates both opportunity and risk. On one hand, AI tools that improve reimbursement accuracy, documentation, and claims processing could become valuable for healthcare providers. On the other hand, if regulators, insurers, or courts determine that certain AI applications create inappropriate billing behavior, some companies could face scrutiny. This is why AI in healthcare will likely remain one of the most regulated and debated areas of the artificial intelligence economy. It can improve efficiency, but it can also raise questions about fairness, accountability, patient privacy, and financial incentives.
There is also the patient side of the story. Previous research showed that patients are increasingly looking for AI-generated health advice, even though the technology has not been proven to be more helpful than other methods for making healthcare decisions. That is a major trivia point because it shows how fast consumer behavior is changing. Years ago, patients searched symptoms on the internet and often ended up on health websites. Today, many people ask AI chatbots for explanations, possible causes, and next steps. That does not mean AI should replace doctors. It should not. But it does show that patients are becoming more comfortable with AI as part of the healthcare experience, whether the healthcare system is ready or not.
Why Wall Street Is Paying Attention to AI-Powered Healthcare Stocks
The investment case for AI-powered healthcare stocks is built on a simple but powerful idea: healthcare is expensive, inefficient, data-heavy, and urgently in need of better tools. Artificial intelligence may not fix everything, but even modest improvements can create large financial effects because the healthcare industry is so massive. If AI can help clinicians see more patients, reduce administrative work, improve clinical accuracy, support diagnosis, lower costs, and speed up drug development, then the companies providing those tools could become major long-term winners.
This is why hedge funds and institutional investors are increasingly watching the space. The best AI healthcare stocks are not just riding a headline trend. Many are operating in markets with durable demand, including diagnostics, drug discovery, robotic surgery, patient engagement, insurance analytics, medical imaging, hospital software, and healthcare data platforms. These companies could benefit as hospitals, clinics, insurers, pharmaceutical firms, and governments adopt AI tools to improve productivity and outcomes. For investors searching for AI stocks to buy now, healthcare stocks with upside, medical technology stocks, biotech AI stocks, digital health stocks, and long-term growth stocks, the sector offers a mix of innovation and necessity.
The key word is necessity. Healthcare systems around the world are dealing with aging populations, chronic disease growth, rising treatment costs, workforce shortages, and increasing patient demand. In that environment, artificial intelligence is not just a luxury upgrade. It could become part of the operating backbone of modern healthcare. The companies that can prove their AI tools save time, reduce costs, improve accuracy, and fit into real clinical workflows may be the ones that attract the most investor attention.
CHECK THIS OUT: Top 10 Small-Cap Biotech Stocks That Could Surge 100% and Top 10 Small-Cap Biotech Stocks With Billion-Dollar Upside Potential.
Our Methodology
To come up with our ranking of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, we used stock screeners to identify healthcare companies with artificial intelligence exposure, narrowed the list to names with recent company-specific developments that could influence investor sentiment, and ranked the final stocks in ascending order based on hedge fund ownership and broader institutional interest.
Top 5 AI-Powered Healthcare Stocks That Can Make You Rich
5. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ranks fifth among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and this is one of the more important biotechnology names on the list because it combines an established commercial drug portfolio with a continuing push into complex disease areas. Trading at $632.90, with the stock up 2.06%, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is backed by 72 hedge fund holders, showing that institutional investors continue to follow the company despite rising competition in some of its most important markets. For investors searching for healthcare stocks to buy, biotech stocks, pharmaceutical stocks, drug development stocks, immunology stocks, and AI-powered healthcare stocks with long-term upside, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a serious name because it is not simply chasing one product cycle. It has a broader research and development platform, a known commercial portfolio, and a pipeline that continues to attract regulatory attention.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration and the European Medicines Agency accepted regulatory applications for cemdisiran, a treatment candidate for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. That sounds highly technical, but the investment story is straightforward: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trying to expand further into serious immune-mediated diseases where treatment options remain important and where effective therapies can create meaningful commercial value. Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder that can cause muscle weakness and fatigue, making it a disease area where improved treatment convenience and durability can matter a lot for patients and physicians.
The FDA granted Priority Review for the cemdisiran new drug application, with a target action date set in November 2026 after the use of a priority review voucher. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) also expects a European Commission decision in the second half of 2027. The filings are backed by data from the Phase 3 NIMBLE trial, which evaluated subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic generalized myasthenia gravis. The dosing schedule is a key detail because convenience matters in chronic disease treatment. A medicine that can be administered every 12 weeks may appeal to patients and clinicians if the safety and efficacy profile is compelling enough. For long-term investors, regulatory acceptance itself is not a final approval, but it is a meaningful step that keeps Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s pipeline story active.
At the same time, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is also dealing with competitive pressure. On the same day, RBC Capital maintained a Sector Perform rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), but the firm described AbbVie’s acquisition of Apogee Therapeutics as a “net negative” for the company. RBC Capital argued that the deal adds fuel to a potential next-generation competitor to Dupixent, one of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s most important products. The concern is that AbbVie brings commercial expertise and long-standing dermatology market relationships behind Apogee’s IL-13 antibody program. In simple market terms, a stronger competitor with a powerful commercial partner can pressure investor sentiment even if the current business remains healthy.
The trivia here is that biotechnology investing is often not just about whether a company has good drugs. It is also about timing, regulatory pathways, patent life, competition, payer coverage, physician adoption, and how quickly a rival can build a better or more convenient therapy. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a well-known brand lineup that includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara, which gives the company more depth than many smaller biotech names. Still, the market will continue watching whether Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) can protect its existing franchises while building new growth drivers from its pipeline.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. For investors looking for best healthcare stocks, AI-powered healthcare stocks, biotech stocks to buy, immunology stocks, rare disease treatment stocks, and long-term pharmaceutical stocks, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a high-quality but closely watched name. Its cemdisiran regulatory progress gives investors a fresh pipeline catalyst, while the competitive noise around Dupixent serves as a reminder that even the strongest healthcare companies must keep innovating to defend their market position.
YOU MUST READ THIS: Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
